therapeutic inertia in the new landscape of multiple sclerosis care
Clicks: 186
ID: 203300
2018
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
185 views
14 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The landscape of multiple sclerosis (MS) treatment is constantly changing. Significant heterogeneity exists in the efficacy and risks associated with these therapies. Therefore, clinicians have the challenge to tailor treatment based on several factors (disease activity level, risk of progression, individual patient preferences and characteristics, personal expertise, etc.), to identify the optimal balance between safety and efficacy. However, most clinicians have limited education in decision-making and formal training in risk management. Together, these factors may lead to therapeutic inertia (TI); defined as the absence of treatment initiation or intensification when therapeutic goals are unmet. TI may lead to suboptimal treatments choices, worse clinical outcomes, and more disability. This article provides a succinct overview on factors influencing TI in MS care.
| Reference Key |
saposnik2018frontierstherapeutic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Gustavo Saposnik;Gustavo Saposnik;Xavier Montalban;Xavier Montalban;Xavier Montalban |
| Journal | journal of photochemistry and photobiology a: chemistry |
| Year | 2018 |
| DOI |
10.3389/fneur.2018.00174
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.